Peripheral T-Cell Lymphoma: FDA Drug Updates

November 9, 2017 - The U.S. Food and Drug Administration (FDA) approved brentuximab vedotin (Adcetris) for the treatment of adult patients with primary cutaneous anaplastic large cell lymphoma (pcALCL) and CD30-expressing mycosis fungoides (MF) who have received prior systemic therapy.  More information.

March 30, 2016 – The U.S. Food and Drug Administration approved defibrotide sodium (Defitelio) for the treatment of adult and pediatric patients with hepatic veno-occlusive disease (VOD), also known as sinusoidal obstructive syndrome, with renal or pulmonary dysfunction following hematopoietic stem-cell transplantation (HSCT). More information.

January 27, 2015 - The U.S. Food and Drug Administration (FDA) approved a same-day delivery device for pegfilgrastim (Neulasta) for non-Hodgkin lymphoma patients who do not need to return to the clinic the day after chemotherapy. More Information

June 3, 2014 - The U.S. Food and Drug Administration approved belinostat (Beleodaq) for the treatment of patients with relapsed or refractory peripheral T-cell lymphoma (PTCL). More Information

August 19, 2011 - The U.S. Food and Drug Administration approved brentuximab vedotin (Adcetris) for the treatment of patients with relapsed or refractory systemic anaplastic large cell lymphoma (ALCL).  More Information.

June 16, 2011 - The U.S. Food and Drug Administration approved romidepsin (Istodax) as a treatment for people with PTCL who have received at least one prior therapy. More Information.

September 25, 2009 - The U.S. Food and Drug Administration approved pralatrexate (Folotyn) for the treatment of patients with relapsed or refractory PTCL. More Information.